Last reviewed · How we verify
Dibromopropamidine (DIBROMPROPAMIDINE)
Dibromopropamidine (generic name: DIBROMPROPAMIDINE) is a dibrompropamidine drug. It is currently in Phase 2 development.
Dibromopropamidine works by binding to the Suppressor of tumorigenicity 14 protein, potentially inhibiting its activity.
Dibromopropamidine is a small molecule with a verified synonym, and it has been studied in a clinical trial as a 0.1% solution for the treatment of Acanthamoeba Keratitis. The study compared dibromopropamidine to a 0.08% PHMB solution and a placebo.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIBROMPROPAMIDINE |
|---|---|
| Drug class | dibrompropamidine |
| Target | Suppressor of tumorigenicity 14 protein, Urokinase-type plasminogen activator, Prothrombin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a 'brake' system to prevent them from growing out of control. The Suppressor of tumorigenicity 14 protein is like a key part of this brake system. Dibromopropamidine is designed to bind to this protein, which could help slow down or stop the growth of abnormal cells.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dibromopropamidine CI brief — competitive landscape report
- Dibromopropamidine updates RSS · CI watch RSS
Frequently asked questions about Dibromopropamidine
What is Dibromopropamidine?
How does Dibromopropamidine work?
What is the generic name of Dibromopropamidine?
What drug class is Dibromopropamidine in?
What development phase is Dibromopropamidine in?
What does Dibromopropamidine target?
Related
- Drug class: All dibrompropamidine drugs
- Target: All drugs targeting Suppressor of tumorigenicity 14 protein, Urokinase-type plasminogen activator, Prothrombin
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing